Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) Shares Sold by Sargent Investment Group LLC

Sargent Investment Group LLC cut its holdings in shares of Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) by 2.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 3,818,000 shares of the company’s stock after selling 105,000 shares during the period. Sargent Investment Group LLC’s holdings in Matinas BioPharma were worth $825,000 at the end of the most recent reporting period.

Separately, Arkadios Wealth Advisors increased its holdings in Matinas BioPharma by 16.1% in the 4th quarter. Arkadios Wealth Advisors now owns 1,624,000 shares of the company’s stock worth $351,000 after acquiring an additional 225,000 shares in the last quarter. Institutional investors own 11.77% of the company’s stock.

Matinas BioPharma Price Performance

NYSEAMERICAN:MTNB remained flat at $0.18 during trading hours on Friday. 1,479,335 shares of the company’s stock were exchanged, compared to its average volume of 1,740,612. Matinas BioPharma Holdings, Inc. has a 52 week low of $0.11 and a 52 week high of $0.89.

Matinas BioPharma (NYSEAMERICAN:MTNB) last released its earnings results on Wednesday, March 27th. The company reported ($0.03) EPS for the quarter.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.